RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for ¹⁸F-FDG of 17 July 2018.

Fludeoxyglucose (¹⁸F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.

Other news

18F-FDOPA now available

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013

Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...

News